Skip to content

Genome Driven Primary Care Clinics - an RCT

Operating Community Primary Care Clinics Under Personalized Medicine Paradigm and Determining Differences in Health Outcomes Between Clinics With and Without Intervention.

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04781205
Enrollment
200000
Registered
2021-03-04
Start date
2019-05-01
Completion date
2029-12-31
Last updated
2021-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genetic Predisposition, Health Services Administration, Microbial Colonization

Keywords

wearable monitors, microbiome, genomic medicine,

Brief summary

A cluster randomized controlled study of 40 primary care clinics in Northern Israel (20 intervention clinics, 20 usual care clinics) to evaluate the value of introducing a precision medicine/genomic approach/paradigm on the clinical and economical outcomes of the clinics. Intervention includes 3 elements: 1. DNA extraction and evaluation (up to the level of WGS); 2. Feces sample for microbiome study, 3. Wearable devices for continuous monitoring of body functions. Expected number of participants is 100,000 in each arm. Results will be calculated for a clinic as a unit and not for individuals (each clinic to be compared to twin selected clinic).

Detailed description

Study major aim: Assess whether employing a paradigm of genomic/precision medicine in primary care clinics can lead to an improvement in the medical or economic outcomes of the clinic as a unit. Specific and secondary aims 1. Study differences in morbidity, mortality, quality of life or the cost of medical service indicators between clinics operating under a genome driven paradigm compared to usual care clinics. 2. Examine whether the public has an interest in extensive genetic testing. 3. Examine whether the medical staff has an interest and ability to assimilate a genomic approach in the routine clinic work. 4. Identify links between genetic markers (mutations, variants) and different diseases (incidence or clinical behavior) or different drug responses (resistance, effectiveness, side-effects). 5. Examine whether the implementation of prolonged personal monitoring devices will lead to improved morbidity and mortality indices. 6. Examine whether measuring genomic variability in the microbiome has implications on health status or means of coping with different diseases and different health conditions.

Interventions

GENETICMutation arrays, NGS panels, GWAS, WES, WGS,

DNA extracted from peripheral blood as well as genetic analysis of bacteria from feces

DEVICEwearable monitors

test various technologies of sensors to measure continuously various body functions and provide information to person and to physician

Sponsors

Carmel Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

Paired cluster randomization of 40 clinics into 20 intervention and 20 usual care. Randomization from among a couple of similar clinics

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All clinic adult population * All diseases

Exclusion criteria

* Mentality unable to understand and sign consent

Design outcomes

Primary

MeasureTime frameDescription
chronic diseases in clinic5 yearswhole clinic Incidence rate/100,000 of major chronic diseases (hypertension, Hyperlipidemia, DM, IHD, Cancer)
Mortality in clinic5 ytearswhole clinic mortality rate/100,000 of major chronic diseases (DM, cancer, IHD)
costs in clinic5 yearsTotal annual cost of clinic activity in NIS, including cost of diagnostic tests and hospitalization

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026